Algernon Pharmaceuticals Announces 25% Enrollment in its Ifenprodil IPF and Chronic Cough Phase 2... Algernon has reached 25% of its enrollment target for its Phase 2 idiopathic pulmonary fibrosis (IPF) and chronic cough clinical study...
Algernon Announces Enrollment of 100 Patients in 2b/3 Human Study for Treatment of COVID-19 Algernon is pleased to announce that it has now enrolled 100 patients, which is two thirds of it enrollment target...
Revive Therapeutics Announces Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 The Company has selected and finalized with five clinical sites in Florida, Texas and California for enrollment of patients in the Phase 3..
Algernon Announces 50% Enrollment in Multinational 2b/3 Human Study for Treatment of COVID-19 Algernon has now enrolled 75 patients, which is 50% of its enrollment target, for its multinational Phase 2b/3 human study of NP-120
Revive Announces IRB Approval of US Expanded Access Treatment Program for Bucillamine in COVID-19 Revive Therapeutics Announces IRB Approval of US Expanded Access Treatment Program (Compassionate Use) for Bucillamine in COVID-19
Revive Enters into Clinical Trial Agreement to Evaluate Psilocybin for Methamphetamine Use Disorder Revive Therapeutics Enters into Clinical Trial Agreement to Evaluate Psilocybin for the Treatment of Methamphetamine Use Disorder
Algernon Announces Enrollment of 50th Patient in 2b/3 Study of Ifenprodil for Treatment of COVID19 Algernon Announces Enrollment of 50th Patient in Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19
Revive Announces IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19 Revive Therapeutics Announces IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19
Revive Therapeutics Announces Submission of IRB Approval for Phase 3 Clinical Trial Protocol for... Revive Therapeutics Announces Submission of IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19
Revive Therapeutics to Expand Phase 3 Clinical Trial for Bucillamine in COVID-19 in Canada & Asia-.. Revive Therapeutics to Expand Phase 3 Clinical Trial for Bucillamine in COVID-19 in Asia-Pacific and Canada
Revive Therapeutics Signs MOU with Attwill Medical Solutions for Phase 3 Clinical Trial for ... Revive Therapeutics Signs MOU with Attwill Medical Solutions for Phase 3 Clinical Trial for Bucillamine in COVID-19 TORONTO, Aug. 14, 202...
Algernon Announces Enrollment of First U.S. Patient in Multinational Phase 2b/3 Human Study of... Algernon Announces Enrollment of First U.S. Patient in Multinational Phase 2b/3 Human Study of Ifenprodil for Treatment of COVID-19 VANCO...
Revive Therapeutics Advancing Drug Delivery Technology for PsychedelicsDeveloped Prototypes of.... Revive Therapeutics Advancing Drug Delivery Technology for Psychedelics Developed Prototypes of Orally Dissolvable Thin Film For Psilocybin
Algernon Announces Enrollment of First Patient in Human Study of Ifenprodil for Treatment of COVID19 Algernon Announces Enrollment of First Patient in 2b/3 Human Study of Ifenprodil for Treatment of COVID-19
Relevium Licenses Patented Science-Based Natural Formulation That Addresses Major Points of Viral... Relevium Licenses Patented Science-Based Natural Formulation That Addresses Major Points of Viral Invasion, Replication and Toxicities
Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for... Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19
Voyageur Signs LOI to Engage THINQ for Pharmaceutical Consulting, and Collaboration on Long Term.... Voyageur Signs LOI to Engage THINQ for Pharmaceutical Consulting, and Collaboration on Long Term Pharmaceutical Drug Development Calgary,...
Algernon Highlights UT Dallas Research Study Identifying Ifenprodil as a Possible COVID-19 Treatment VANCOUVER, British Columbia, July 21, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (...
Algernon Announces First U.S. Clinical Trial Site in Florida for Phase 2b/3 Human Study of Ifenpro.. Algernon Announces First U.S. Clinical Trial Site in Florida for Phase 2b/3 Human Study of Ifenprodil for COVID-19 VANCOUVER, British Col...
Relevium Announces CleanCare Expansion into Disinfection and Personal Protection and Appoints the... Relevium Announces CleanCare Expansion into Disinfection and Personal Protection and Appoints the PaperStore as Official Retailer for Nor...
Algernon Begins Screening Patients for Phase 2 Ifenprodil IPF and Chronic Cough Human Study in Aus.. Algernon Begins Screening Patients for Phase 2 Ifenprodil IPF and Chronic Cough Human Study in Australia VANCOUVER, British Columbia, Jul...
Relevium Welcomes Award-Winning Marketing Executive to its Advisory Board. JUNE 23, 2020 - MONTREAL, QUEBEC – Relevium Technologies Inc. (TSX.V: “RLV”, OTC: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevi...
Sernova Highlights Positive Results Presented at the American Diabetes Association's Virtual 80th.. Sernova Highlights Positive Results Presented at the American Diabetes Association's Virtual 80th Scientific Sessions LONDON, ONTARIO - T...
